공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

자궁근종절제술 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Myomectomy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 1008446
페이지 정보 영문
가격
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)


자궁근종절제술 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Myomectomy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 자궁근종절제술 시장은 2021-2026년간 약 9.8%의 연평균 복합 성장률(CAGR)로 성장할 전망입니다.

COVID-19 팬데믹의 영향은 자궁근종절제술 시장에 중대한 영향을 미치고 있습니다. 헬스케어 서비스가 COVID-19 환자에게 자원을 할당한 결과 병원은 긴급시술을 우선시하고 자궁근종절제술 등의 선택적 시술을 지연 또는 연기했기 때문에 몇 개월간 수술을 기다리는 환자가 증가했습니다. 상태가 정상으로 돌아오면 자궁근종절제술 시장은 서서히 회복될 것으로 예상됩니다.

자궁근종 환자수 증가는 자궁근종절제술 시장 성장에 기여하는 중요한 요인입니다. 합병증 감소와 병원 체재일 감소에 의한 저침습수술 증가는 시장 성장을 뒷받침합니다. 품질 높은 효율적인 치료를 제공하기 위한 로봇 및 복강경 수술 부상 등의 기술적 발전이 자궁근종절제술 시장 성장에 더욱 기여할 것입니다. 시장에는 혁신과 제품 개발 성장을 위한 몇 가지 기회가 존재하지만, 자궁근종절제술에는 자체의 위험이 따릅니다. 이러한 요인들과 함께 새로운 의료기기 비용이 높아지면 자궁근종절제술 시장 성장에 방해가 될 가능성이 있습니다.

세계의 자궁근종절제술(Myomectomy) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, 유형별/지역별 시장 규모 추이와 예측, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 성장 추진력
    • 자궁근종 환자 증가
    • 저침습 수술 증가
    • 기술 발전
  • 시장 성장 억제요인
    • 의료기기의 고비용
    • 치료에 관련된 합병증
  • Porter의 산업 분석

제5장 시장 세분화

  • 유형별
    • 복부
    • 복강경
    • 자궁경
    • 로봇
  • 제품별
    • Laparoscopic Power Morcellators
    • Harmonic Scalpel
    • Laparoscopic Sealer
    • 기타
  • 최종사용자별
    • 클리닉/병원
    • 외래수술센터
  • 지역
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제6장 경쟁 구도

  • 기업 개요
    • Medtronic plc
    • Stryker Corporation
    • ConMed Corporation
    • INSIGHTEC Ltd
    • CooperSurgical Inc.
    • Hologic Inc.
    • Intuitive Surgical Inc.
    • KARL STORZ SE &Co. KG
    • B Braun
    • Richard Wolf Medical Instruments
    • Minerva Surgical Inc.

제7장 시장 기회와 동향

LSH 21.06.18

The global myomectomy market is projected to register a CAGR of nearly 9.8% over the forecast period.

The impact of the COVID-19 pandemic is significant on the Myomectomy market. With the surge of COVID-19 cases around the world, healthcare services diverted resources towards the patients suffering from COVID-19 disease. Guidelines and recommendations were provided for the management of patients during the pandemic. This resulted in hospitals prioritizing emergency procedures and delaying or postponing elective procedures such as myomectomy surgery leading to a backlog of patients waiting for their surgeries for months. A CovidSurg Collaborative study, 2020, estimated around 28 million operations would be delayed during peak 12-week disruption due to COVID-19 including 81.7% benign surgeries. With conditions returning to normal, myomectomy procedures are expected to recover gradually.

An increase in the number of patients suffering from uterine fibroids will be the key factor contributing to the growth of the Myomectomy market. According to the United States Department of Health and Human Services, Office on Women's Health fibroids are common in women in their 40's and 50's and about 20-80% of women develop fibroids by the time they reach 50. A research study published in 2018 involving women diagnosed with uterine fibroids, myectomy and endometrial ablation remained as the most opted surgical procedure. Another research study published in 2017 including approximately 5000 Italian women with uterine fibroids showed that 95% of surgeries performed included women between the age of 36-55. Additionally, rise in minimally invasive surgical procedures due to less complications and reduced stay at hospitals will drive the growth of the market. Technological advancements such as rise in robotic and laparoscopic-assisted surgery to deliver quality and efficient treatment will further contribute to the Myomectomy market.

Though the market holds several opportunities for growth in innovation and product developments, myomectomy procedure is associated with its own risks. According to a research study published in 2020 by Thieme, hemorrhage was the most common complication in abdominal myomectomy procedures and 13% of hysteroscopic myomectomy procedures observed complications such as excessive bleeding, uterine perforation, fluid overload, and postoperative infection. Research studies concluded that higher recurrence rate of myoma was observed with laparoscopic myomectomy. Along with these factors, higher costs of new medical devices might restrict the growth of the Myomectomy market.

Key Market Trends

Abdominal Type of Myomectomy Is Expected to Occupy a Significant Share over the Forecast Period

Due to the COVID-19 pandemic, all elective procedures were postponed prioritizing services for COVID-19 patients. In March 2020, the American College of Surgeons has provided COVID-19 guidelines for the triage of gynecology patients. According to this, myomectomy procedures were classified under surgeries that can be delayed by several months. Similarly in May 2020, the Royal College of Obstetricians and Gynecology published a prioritization framework for care in response to COVID-19 which classifies myomectomy under priority 3 and priority 4 indicating the procedure can be delayed up to and over 3 months based on causing anemia. These guidelines resulted in surgeons delaying myomectomy procedures which will impact devices used in the myomectomy market. Recovery of these backlog procedures will occur gradually adding to the market growth.

Abdominal type, also known as open type, is considered classic myomectomy surgery. This procedure is performed by making a small horizontal incision or vertical for a larger uterus across the abdomen region of the body. With the rise in patients with uterine fibroids, the demand for myomectomy procedures will also increase. Abdominal myomectomy is mostly performed and highly preferred type of treatment. A United Kingdom research study published on Gynecological Surgery, Springer Open in 2017 involving physician consultants identifies that nearly 70% of them perform open myomectomy. The open type is preferred based on size and location of fibroids. Hence, such activities across different countries, the procedures are expected to grow more over the forecast period. Further, slow down of COVID-19 impact and increase in medical product supplies across countries will collectively drive the growth of the market.

North America is Expected to Dominate the Myomectomy Market Over the Forecast Period

United States experienced a huge impact due to COVID-19. The Healthcare sector had to direct services towards COVID-19 patients management and vaccine development. Guiding committees and regulatory bodies published guidelines to be followed for patients and physicians. Elective procedures had to be postponed and only emergency procedures got high importance. Recovery of these backlog procedures will take place slowly considering the pandemic situation and resurgence of the disease.

However, North America is expected to dominate the Myomectomy market over the forecast period due to the rise in the prevalence of uterine fibroid. A 2018 published article in the American Journal of obstetrics and gynecology shows that the prevalence of uterine fibroids was found to be 10% in the United States with higher occurring rates observed for black women and other ethnic or racial groups. Additionally, according to the World Economic Outlook 2021 by IMF, real GDP is projected to grow by 6.4% in the United States and 5% in Canada. These factors along with high reimbursement rates and government initiatives contribute to North America occupying the largest share within the Myomectomy market.

Asia-Pacific is expected to grow at higher CAGR over forecast period due increasing GDP projected at 8.6% in 2021, public awareness, government initiatives towards healthcare and increased expenditure.

Competitive Landscape

The Myomectomy Market remains highly competitive with major key players dominating the market. Technological advancements and product innovation will provide new opportunities to compete within the market. The rise in laparoscopic and robotic-assisted myomectomy due to its advantages over traditional methods will drive the growth of the market. Some of the major players include Medtronic plc, Stryker Corporation, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc, Hologic Inc, KARL STORZ SE & Co. KG, B Braun, Richard Wolf Medical Instruments, and Minerva Surgical Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Number of Patients Suffering from Uterine Fibroids
    • 4.2.2 Rise in Minimally Invasive Procedures
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Medical Devices
    • 4.3.2 Complications Associated with the Procedure
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Abdominal
    • 5.1.2 Laparoscopic
    • 5.1.3 Hysteroscopic
    • 5.1.4 Robotic
  • 5.2 By Product
    • 5.2.1 Laparoscopic Power Morcellators
    • 5.2.2 Harmonic Scalpel
    • 5.2.3 Laparoscopic Sealer
    • 5.2.4 Others
  • 5.3 By End User
    • 5.3.1 Clinics/Hospitals
    • 5.3.2 Ambulatory Surgical Centers
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic plc
    • 6.1.2 Stryker Corporation
    • 6.1.3 ConMed Corporation
    • 6.1.4 INSIGHTEC Ltd
    • 6.1.5 CooperSurgical Inc.
    • 6.1.6 Hologic Inc.
    • 6.1.7 Intuitive Surgical Inc.
    • 6.1.8 KARL STORZ SE & Co. KG
    • 6.1.9 B Braun
    • 6.1.10 Richard Wolf Medical Instruments
    • 6.1.11 Minerva Surgical Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q